---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-028372"
form_type: "8-K"
ticker: "AUTL"
cik: "0001730463"
company_name: "Autolus Therapeutics plc"
filed_at: "2024-02-08T23:59:59+00:00"
generated_at: "2026-06-06T05:44:06.311024+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Autolus prices $350M ADS offering at $6.00 per ADS for obe-cel development

## Summary
- Offering of 58,333,336 ADSs at $6.00/ADS for gross proceeds of $350 million.
- Net proceeds to fund obe-cel clinical development, manufacturing, and commercial infrastructure.
- Additionally expects $250 million from BioNTech under license/option agreement and private placement.
- Offering expected to close February 12, 2024; Jefferies and Truist are joint bookrunners.

## SEC filing metadata
- accession: 0001193125-24-028372
- form_type: 8-K
- ticker: AUTL
- cik: 0001730463
- company_name: Autolus Therapeutics plc
- filed_at: 2024-02-08T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1730463/000119312524028372/0001193125-24-028372-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1730463/000119312524028372/d745010d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-028372
- JSON: https://secwatch.observer/filing/0001193125-24-028372.json
- Plain text: https://secwatch.observer/filing/0001193125-24-028372.txt

## Key facts
- Material Agreements
  Autolus Therapeutics plc entered into Underwriting Agreement with Jefferies LLC and Truist Securities, Inc. as representatives of the several underwriters named therein valued at $350 million (effective 2024-02-08).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: Jefferies LLC and Truist Securities, Inc. as representatives of the several underwriters named therein
  - Value: $350 million
  - Effective: 2024-02-08
  source text: On February 8, 2024, Autolus Therapeutics plc (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with Jefferies LLC and Truist Securities, Inc. as representatives of the several underwriters named therein (the “ Underwriters ”), in connection with the issuance and sale by the Company in an underwritten registered direct offering (the “ Offering ”) by the Company of 58,333,336 American Depositary Shares (“ ADSs ”) representing 58,333,336 ordinary shares of the Company at an offering price of $6.00 per ADS. Gross proceeds from the Offering, before deducting underwriting discounts and commissions and offering expenses payable by the Company, are expected to be $350 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1730463/000119312524028372/0001193125-24-028372-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.